Biodesix, Inc. reports developments as a diagnostics solutions company focused on lung disease testing and biopharma development services. Its updates center on Diagnostic Tests such as Nodify Lung® Nodule Risk Assessment, Nodify CDT® and IQLung® Cancer Treatment Guidance, along with blood- and tissue-based testing, proteomic and genomic approaches, and development work for life sciences partners.
Recurring news also covers quarterly results, revenue guidance, test-volume trends, clinical validation studies, real-world evidence presentations at medical meetings, and the company’s efforts to expand evidence for lung nodule management and oncology testing applications.
Biodesix, Inc. (Nasdaq: BDSX) has successfully closed its initial public offering (IPO) of 4,000,000 shares at a price of $18.00 per share, raising approximately $72.0 million in gross proceeds. The shares began trading on The Nasdaq Global Market on October 28, 2020. Morgan Stanley and William Blair led the offering, with Canaccord Genuity and BTIG participating as managers. The offering's registration has been declared effective by the U.S. Securities and Exchange Commission. This announcement does not constitute an offer to sell or buy the securities.
Biodesix (Nasdaq: BDSX) announced the pricing of its initial public offering (IPO) of 4,000,000 shares at $18.00 per share. Trading on The Nasdaq Global Market is set to begin on October 28, 2020, with the IPO expected to close on October 30, 2020, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 600,000 shares at the IPO price. Morgan Stanley and William Blair are the lead managers for this offering, which has been registered and declared effective by the U.S. Securities and Exchange Commission.